Psychedelic-assisted psychotherapy: The Australian and general practice perspective
Australian Journal of General Practice February 1, 2026 DOI: 10.31128/ajgp-12-24-7494 via OpenAlex
Summary
AI-generated from the abstractSince July 2023, Australia has made two psychedelic medicines available in the private sector for psychotherapeutic treatment, allowing general practitioners to refer patients with treatment-resistant depression or PTSD. These medicines can help patients access subconscious emotions, thoughts, beliefs, and traumatic memories that are otherwise difficult to reach. Meta-analyses of clinical trials have shown substantial effect sizes, though not everyone is suited to or will respond to this treatment. GPs can expect to play a role in referring and supporting patients, as ongoing trials continue to clarify the indications, efficacy, and safety of psychedelic therapy.
Study at a glance
| Characteristics | Review Peer reviewed |
|---|---|
| Population | Patients with treatment-resistant PTSD and depression |
| Keywords | Subconscious Perspective graphical General practice Clinical practice Clinical trial |
| Citations | 1 |
| Key finding | Psychedelic-assisted psychotherapy is now available privately in Australia for treatment-resistant PTSD and depression, with meta-analyses showing substantial effect sizes, though not all patients are suitable candidates. |
Abstract
BACKGROUND: Since Australia's Therapeutic Goods Administration down-scheduled two psychedelic medicines from July 2023, psychotherapeutic treatment using these medicines has become available in the private sector, making it possible for general practitioners (GPs) to refer their patients with treatment-resistant depression or post-traumatic stress disorder (PTSD). Several other psychedelic medicines are also legally in use as off-label or unapproved medicines. OBJECTIVE: The aim of this article is to help GPs make sense of this new type of treatment by discussing the Australian context, with focus on what a GP can expect for their patient and the GP's potential role. DISCUSSION: Psychedelic medication, when used to facilitate a psychotherapy process, can provide a very different and powerful way to allow patients to access emotions, thoughts, beliefs and traumatic memories that may otherwise remain subconscious or hard to access. This treatment is currently available privately in Australia for patients with treatment-resistant PTSD and depression. Meta-analyses of clinical trial results to date have shown some substantial effect sizes. Such trials continue to clarify and expand indications, efficacy and safety, as not everyone is suited to, safe for or will respond to psychedelic treatment.